Novartis Cancer, Heart Drugs Disappoint as Company Lifts Targets

Finance
sreda, 30. oktober 2024 ob 05:00
While Novartis provided an optimistic take on 2024, the lack of commentary on 2025 “may disappoint,” Bloomberg Intelligence analyst John Murphy said in a note

Opozorilo: Po 297. členu Kazenskega zakonika je posameznik kazensko odgovoren za javno spodbujanje sovraštva, nasilja ali nestrpnosti.


Vpišite prikazane znake


 

Google Translate

English Croatian French German Italian Spanish Serbian Slovenian Hungarian